Douglas Lane & Associates LLC Purchases 6,526 Shares of Johnson & Johnson (NYSE:JNJ)

Douglas Lane & Associates LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 599,386 shares of the company’s stock after acquiring an additional 6,526 shares during the period. Johnson & Johnson makes up approximately 1.2% of Douglas Lane & Associates LLC’s investment portfolio, making the stock its 21st largest position. Douglas Lane & Associates LLC’s holdings in Johnson & Johnson were worth $86,683,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Vinva Investment Management Ltd boosted its stake in shares of Johnson & Johnson by 6.8% in the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after buying an additional 7,110 shares during the period. Financial Counselors Inc. raised its holdings in Johnson & Johnson by 5.3% in the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after acquiring an additional 9,309 shares in the last quarter. Meridian Investment Counsel Inc. lifted its position in shares of Johnson & Johnson by 19.6% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock valued at $3,667,000 after acquiring an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Johnson & Johnson by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after purchasing an additional 102,502 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in Johnson & Johnson in the third quarter valued at about $69,859,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Bank of America restated a “neutral” rating and set a $166.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Guggenheim raised their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $4.00 during trading on Wednesday, reaching $142.23. The company’s stock had a trading volume of 6,437,406 shares, compared to its average volume of 6,856,921. The firm has a market cap of $342.44 billion, a price-to-earnings ratio of 20.58, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The firm has a 50 day moving average of $150.75 and a 200-day moving average of $156.23. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 12 month low of $141.44 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.66 EPS. Research analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.